Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech, Inc. (NASDAQ: SNES) has appointed Joel Fruendt as its new Chief Executive Officer, succeeding Ken Siegel, who will retire at the year's end while remaining as an Executive Director during the transition. Fruendt brings over 15 years of experience in the pest control industry, previously holding senior roles at Clarke Environmental Inc. and a global manufacturing firm. His appointment aligns with SenesTech's strategy to enhance the commercialization of ContraPest, its EPA-registered rodent fertility control product, aiming for sustainable pest management solutions.
SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the third quarter of 2022, ending September 30, 2022, on November 14, 2022, before market open. A conference call will follow at 11:00 am ET to discuss the findings. The company focuses on innovative pest control through its patented product, ContraPest, designed to manage rat populations sustainably. Stakeholders can access the call via phone or live webcast and will have a replay option for later review.
SenesTech, Inc. (NASDAQ: SNES) will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company specializes in managing animal pest populations through fertility control, particularly focusing on rat populations. A webcast of their presentation will be available at 9:00am ET on September 28, and it will be archived for later replay. Additionally, management will hold virtual one-on-one meetings during the conference. SenesTech is known for ContraPest, the first U.S. EPA-registered rodent contraceptive.
SenesTech, Inc. (NASDAQ: SNES) has declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock for each outstanding share of common stock held as of September 5, 2022. This Series C Preferred Stock will have significant voting rights concerning amendments to the company's charter. Unvoted shares will be redeemed for $0.001 in cash. The company plans to file a report with the SEC and a special meeting notice regarding a potential reverse stock split. SenesTech is known for its eco-friendly rodent fertility control product, ContraPest.
SenesTech, Inc. (NASDAQ: SNES) reported record second quarter 2022 product sales, achieving a 73% year-over-year increase and a 42% sequential rise. Sales reached approximately $277,000, driven by e-commerce growth, including a boost from the Ecosystems Protection Act of 2021. The launch of the Elevate Bait System contributed to this surge, with 1,500 units shipped in just nine days. Despite a net loss of $(2.6 million), gross profit improved to 49%. The company anticipates continued growth in diverse segments, including zoos and agricultural markets.
SenesTech (NASDAQ: SNES) announced significant efficacy results for its contraceptive product, ContraPest, in zoo deployments. Following its use starting in December 2021, a major U.S. zoo reported a dramatic decrease in rat populations, allowing successful breeding of endangered birds for the first time in years. ContraPest has shown up to 90% efficacy improvement over traditional pest management methods. SenesTech has expanded its zoo customer base by over 300% in the past year, presenting a multimillion-dollar growth opportunity.
SenesTech, Inc. (NASDAQ: SNES) will announce its second quarter 2022 financial results on August 11, 2022, after market close. A conference call is scheduled for the same day at 5:00 pm ET to discuss these results. The company specializes in pest control through its proprietary contraceptive product, ContraPest, aimed at managing rat populations sustainably. Details for the teleconference and live webcast are provided for interested parties. For more information, visit their website.
SenesTech, Inc. (SNES) announced that its innovative Elevate Bait System with ContraPest, the only EPA registered birth control for rats, is now available for purchase nationwide, including California. This system targets roof rats effectively, especially in agricultural settings. Since its initial launch, the system has gained rapid traction, and CEO Ken Siegel highlighted significant customer interest following approval from the California Department of Pesticide Regulation. The product aims to reduce rat populations, which can reproduce exponentially, with the potential to eliminate infestations more efficiently.
SenesTech, Inc. (SNES) has launched the Elevate Bait System, an innovative EPA-registered birth control solution for roof rats, now available for purchase in the U.S. The system is designed for deployment in elevated indoor spaces to effectively target and control rat populations. This follows successful trials, showing a 95% reduction in rat activity on poultry farms after using ContraPest. The system allows easy maintenance and has received EPA approval, except in California. This breakthrough aims to combat the rising roof rat populations causing significant property damage and health risks.
SenesTech (NASDAQ: SNES) reported a remarkable 122% increase in first-quarter 2022 sales, reaching approximately $195,000, compared to $88,000 the previous year. The launch of the Elevate Bait System™ with ContraPest is anticipated to enhance market penetration, particularly in agriculture, targeting above-ground rat infestations. Despite revenue growth, the company experienced a net loss of $(2.3) million, up from $(1.8) million in Q1 2021. Cash reserves stand at approximately $7.2 million. CEO Ken Siegel emphasized ongoing sales success and innovative market solutions.